ANAVEX LIFE SCIENCES CORP. (AVXL) Form 8-K — Jul 30, 2026

$AVXLForm 8-KItems 2.02, 9.01Filed Jul 30, 2026, 8:15 AM ET0001731122-26-000988Original filing

Anavex Life Sciences reported preliminary financial results for the second quarter of fiscal 2026, revealing a net loss of $5.3 million, or $0.06 per share, a significant improvement from the net loss of $11.2 million in the same period last year. The company ended the quarter with cash and cash equivalents of $127.4 million, an increase from $102.6 million at the end of fiscal 2025. Management stated that the current cash balance is expected to fund operations into mid-to-late fiscal 2028, extending the company's runway.

Key figures

Eps: -0.06
Cash Position: 127422000
Runway: mid-to-late fiscal 2028
Rd Expenses Q2 2025: 9892000
Rd Expenses Q2 2026: 4192000

Price after filing

1 day: -3.1%7 days: +27.6%30 days: +16.3%

Close on the filing date to close N calendar days later (from $2.57). Historical, not a forecast.

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.